Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clostridium butyricum GKB7
- Development stage
- Unknown
- Lead developer
- Grape King Bio
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Clostridium butyricum GKB7 is a specific live probiotic strain of the butyrate-producing, Gram-positive anaerobic bacterium *Clostridium butyricum*. Developed by Grape King Bio, this strain is being investigated for its therapeutic potential through the modulation of the gut-brain-behavior axis and its anti-inflammatory properties. In clinical research, it is being evaluated for its efficacy in improving behavioral symptoms and identifying diagnostic biomarkers in patients with Autism Spectrum Disorder (ASD). Additionally, preclinical studies have demonstrated that oral administration of GKB7 can ameliorate signs of osteoarthritis by reducing the expression of pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), thereby protecting cartilage and bone from degenerative damage.
- Other names
- C. butyricum GKB7Clostridium butyricum strain GKB7
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on clostridium butyricum GKB7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clostridium butyricum GKB7.